CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CCI-06-00093
Health/Science/Disease Category:
Primary Immune Deficiency Disorders (PIDD)
Short Name:
PBT IVIG Protocol 2004C009G
Full Title of Study:
A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases
Phase/Type of Study:
Phase 3
Purpose of Research:
Two main purposes of the study: To see if serious bacterial infections occur less than once a year in each study subject. This will determine if study drug is effective. Also to find out if study drug is safe and tolerable for study subjects.
Eligibility:
Males and Females between the ages of 2 and 80 years old with established diagnosis of PIDD who are on a stable dose of immune globulin administered intravenously.
Time Commitment/Requirements:
Participants will receive the study drug 1 time every 3 weeks or every 4 weeks for a 12 month period.
Primary Investigator:
Dr. Joseph Church
Coordinator Contact Name:
Sydney Brown or Janet Jaime
Phone Number:
323-361-2501 or 323-361-4537
Email:
sybrown@chla.usc.edu or pyong@chla.usc.edu